Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,280 across all filing types
Latest filing 2025-04-28 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
2024年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2024 年年度报告全文" which translates to "2024 Annual Report Full Text" for 广州市香雪制药股份有限公司 (Guangzhou Xiangxue Pharmaceutical Co., Ltd.). It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, and financial statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes audited financial data, management analysis, and comprehensive disclosures. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2024
2025-04-28 Chinese
2024年度商誉减值测试报告
Annual Report Classification · 95% confidence The document is titled as a 2024 annual report on goodwill impairment for 广州市香雪制药股份有限公司. It contains detailed financial data and analysis related to goodwill impairment testing, including asset group valuations, impairment indicators, assumptions, cash flow projections, discount rates, and impairment loss calculations. The document is substantive and focused on a specific financial topic within the annual reporting period. It is not a brief announcement or a certification letter, but a detailed financial report segment. Therefore, it fits best under the category of Annual Report (10-K), which covers official yearly reports with full financial performance details. FY 2024
2025-04-28 Chinese
关于未弥补亏损达到实收股本总额三分之一的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the company's accumulated losses reaching one-third of its paid-in capital. It includes details about the financial situation, causes of losses, and measures to address the issues. The document references audited financial statements but does not contain the full financial report itself. It is a formal disclosure about a significant financial condition requiring shareholder meeting consideration, typical of a regulatory announcement. The document length is short (1330 characters), and it serves as a public notice rather than a full financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-04-28 Chinese
2024年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2024 by 广州市香雪制药股份有限公司. It discusses the company's internal control system, evaluation of its effectiveness as of December 31, 2024, and details about internal control deficiencies and their rectifications. The content is focused on internal control evaluation, risk assessment, control activities, and internal audit results, which aligns with an audit-related report rather than a full annual report or interim financial report. The document length is 9187 characters, which is substantial and contains detailed evaluation and conclusions about internal controls, not just an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2024
2025-04-28 Chinese
2024年年度财务报告
Annual Report Classification · 100% confidence The document is titled as the 2024 annual financial report of 广州市香雪制药股份有限公司 and contains detailed sections including an audit report with an unqualified opinion, audit opinion date (April 28, 2025), audit firm name, and names of certified public accountants. It includes comprehensive financial statements such as consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and detailed notes on accounting policies and key audit matters like revenue recognition, accounts receivable impairment, and development expenditure impairment. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. The presence of full financial statements and audit opinion confirms this is the official annual report covering the company's full financial performance for the fiscal year ending December 31, 2024. Therefore, the document fits the definition of an Annual Report (10-K). FY 2024
2025-04-28 Chinese
2024年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled '2024 年度董事会工作报告' which translates to '2024 Annual Board Work Report' and details the board's activities, meetings, resolutions, and governance practices over the year 2024. It includes comprehensive information on the board's work, committee activities, financial performance summaries, and plans for 2025. The content is focused on the board's governance and operational oversight rather than presenting full financial statements or audit results. It is not a full Annual Report (10-K) or Audit Report (AR), nor is it a simple announcement or certification. The document fits best under Board/Management Information (MANG) as it reports on the board's work and management activities during the year.
2025-04-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.